Next Article in Journal
Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience
Next Article in Special Issue
The STAT3-Regulated Autophagy Pathway in Glioblastoma
Previous Article in Journal
Renin–Angiotensin System Antagonism Protects the Diabetic Heart from Ischemia/Reperfusion Injury in Variable Hyperglycemia Duration Settings by a Glucose Transporter Type 4-Mediated Pathway
Previous Article in Special Issue
Cyclooxygenase-2 (COX-2) as a Target of Anticancer Agents: A Review of Novel Synthesized Scaffolds Having Anticancer and COX-2 Inhibitory Potentialities
 
 
Review

Article Versions Notes

Pharmaceuticals 2023, 16(2), 240; https://doi.org/10.3390/ph16020240
Action Date Notes Link
article pdf uploaded. 5 February 2023 09:03 CET Version of Record https://www.mdpi.com/1424-8247/16/2/240/pdf-vor
article xml file uploaded 21 February 2023 11:10 CET Original file -
article xml uploaded. 21 February 2023 11:10 CET Update https://www.mdpi.com/1424-8247/16/2/240/xml
article pdf uploaded. 21 February 2023 11:10 CET Updated version of record https://www.mdpi.com/1424-8247/16/2/240/pdf
article html file updated 21 February 2023 11:11 CET Original file https://www.mdpi.com/1424-8247/16/2/240/html
Back to TopTop